X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: ABD-147
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: ABD-147
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2024
Details:
The financing will be used to engineer and advance best-in-class antibody-based radiopharmaceuticals, including ABD-147, for cancer, by leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals.
Lead Product(s): ABD-147
Therapeutic Area: Oncology Product Name: ABD-147
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $142.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
